Novavax has inked another settlement for a past COVID-19 vaccine supply deal. The Maryland biotech has agreed to pay $123.8 million to end a COVID vaccine supply pact with the UK Health Security ...
Novavax (NasdaqGS:NVAX) has been removed from multiple major Russell growth indices. The changes follow the latest Russell ...
It may seem like a similar story for investors but Novavax has obtained approval for a COVID-19 vaccine -- yet again. On Aug. 30, the healthcare company announced that the Food and Drug Administration ...
On May 10, Novavax announced a co-exclusive licensing agreement with healthcare giant Sanofi. The companies are going to work together on commercializing Novavax's adjuvanted COVID-19 vaccine ...
Nov 5 (Reuters) - Novavax (NVAX.O), opens new tab said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency (UKHSA) related to its COVID-19 ...
Zacks.com on MSN
Novavax (NVAX) Stock Moves 1.36%: What You Should Know
In the latest trading session, Novavax (NVAX) closed at $9.59, marking a +1.36% move from the previous day. Meanwhile, the ...
It was 2020 and Maryland biotech Novavax was thinking big. It had a plan to become a COVID vaccine powerhouse, with enough manufacturing capacity to supply the U.S. all by itself, as its executives ...
Under the non-exclusive agreement, Pfizer will utilize Novavax’s Matrix-M adjuvant in products across two disease areas, with Novavax receiving a $30 million upfront payment. Additionally, the ...
The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 vaccine as a post-approval commitment, a source familiar with the matter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results